外国人教授・Dr. Rhodri Jones先生ご退官のお知らせ
当講座のRhodri Jones教授が平成２８年３月末日をもちまして ご退職されました。
在職中は、欧州（英国）の再生医療を取り巻く法規制や最新 トレンドを含めた大変興味深い授業を行い、医学生教育に ご貢献なされました。また、English Salonのレギュラー 講師陣の一人としてご活躍されました。
Next Generation Medicine: Where Do We Go From Here?
場所：九州大学 基礎研究A棟 第一講義室
Kyushu University, Faculty of Medical Sciences Building A of Basic Sciences, Lecture Hall#1
My two years in Kyushu University have coincided with rapid developments in stemcell therapy and in tissue engineering. These advances have provided many interestingtopics for my lectures and have also generated ethical dilemmas which need to beresolved. We have seen the development of therapies with a huge potential to treat theever increasing number of aging patients – those whose quality of life would otherwisebe poor. This is a worthwhile area of study but there has been too little discussionabout the cost ofthese therapies and who will, ultimately, pay for them. I shall addressthese topics in my lectureand offer some insights into the ethical and financialimplications of next generation medicine. I shall continue my talk with some data from my research work in medical innovation inthe UK,including some comments on the UK regulatory frameworks under which these studiesare carried out. I am working with a clinical neuroscience group aiming at therapeuticstrategies for multiple sclerosis (MS), using mesenchymal stem cells ‘engineered’ todifferentiate into neuronal lineages. We are studying the optimal cell type fortherapeutic utility and he role of the immune response in exacerbating MS: shouldwe target the pathology or the aberrant immune response (or both)? I have also been involved in a study aiming to track cells in real time usingnanosensor technology,where cell fate can be determined and consequent changes in cellmetabolism can be recorded.In one study, we have changed the cell metabolism by introducing nanosenors loaded withpro-inflammatory precursor molecules, as a potential therapeutic strategy in a numberof disorders. Can these technologies be used in the clinic? Finally, I shall being the two threads together in a broad discussion about futuredirections and how robust strategies are needed to continue the momentum of translationalmedicine into the next generation.